- Home
- LXRX vs JRI Comparison
LXRX vs JRI Comparison
Compare LXRX & JRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- JRI
- Stock Information
- Founded
- LXRX 1995
- JRI 2012
- Country
- LXRX United States
- JRI United States
- Employees
- LXRX N/A
- JRI N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- JRI Finance Companies
- Sector
- LXRX Health Care
- JRI Finance
- Exchange
- LXRX Nasdaq
- JRI Nasdaq
- Market Cap
- LXRX 428.8M
- JRI 367.7M
- IPO Year
- LXRX 2000
- JRI N/A
- Fundamental
- Price
- LXRX $1.19
- JRI $13.44
- Analyst Decision
- LXRX Buy
- JRI
- Analyst Count
- LXRX 5
- JRI 0
- Target Price
- LXRX $3.23
- JRI N/A
- AVG Volume (30 Days)
- LXRX 2.4M
- JRI 68.0K
- Earning Date
- LXRX 08-06-2025
- JRI 01-01-0001
- Dividend Yield
- LXRX N/A
- JRI 9.38%
- EPS Growth
- LXRX N/A
- JRI N/A
- EPS
- LXRX N/A
- JRI N/A
- Revenue
- LXRX $58,432,000.00
- JRI N/A
- Revenue This Year
- LXRX N/A
- JRI N/A
- Revenue Next Year
- LXRX N/A
- JRI N/A
- P/E Ratio
- LXRX N/A
- JRI N/A
- Revenue Growth
- LXRX 1504.83
- JRI N/A
- 52 Week Low
- LXRX $0.28
- JRI $9.70
- 52 Week High
- LXRX $2.18
- JRI $12.12
- Technical
- Relative Strength Index (RSI)
- LXRX 56.85
- JRI 60.54
- Support Level
- LXRX $1.12
- JRI $13.27
- Resistance Level
- LXRX $1.27
- JRI $13.46
- Average True Range (ATR)
- LXRX 0.09
- JRI 0.08
- MACD
- LXRX -0.00
- JRI 0.00
- Stochastic Oscillator
- LXRX 68.00
- JRI 89.29
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About JRI Nuveen Real Asset Income and Growth Fund of Beneficial Interest
Nuveen Real Asset Income and Growth Fund is the United States-based closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.